Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS
Contenuto archiviato il 2024-06-10

Field studies of pneumococcal conjugate vaccines to prevent ari in South East Asia - effectiveness of an 11-valent vaccine; safety and immunogenicityof a 4-valent vaccine under development

Obiettivo

To find an effective primary prevention for a significant fraction of acute respiratory infections (ARI), especially of severe ARI and related severe disease in infants and children in developing countries.

Specifically to:
* prepare, initiate, and carry out the first half of an effectiveness study with a new 11-valent pneumococcal conjugate vaccine (Pnc-c) using meningococcal A,C as control, and administered within the national immunization programme (EPI) on the island of Bohol, the Philippines
* assess safety and immunogenicity in both industrialized and developing country settings (Finland, Vietnam) of the 4-valent Pnc-c developed by the Dutch-Nordic consortium
Expected Outcome

Demonstrate the immunogenicity and safety of the suggested Pnc-c vaccines. The study, once completed, will provide evidence on the efficacy, effectiveness and cost-benefits and establish serological correlates for protection of the 11-valent Pnc-c. The results will be directly and immediately applicable to countries of the South East Asian region, and more widely to developing countries with a moderate infant mortality rate of 40-60 / 1000. In addition, these studies will strengthen the skills of collaborating researchers in both developing and developed countries to perform small and large scale vaccine trials according to the GCP requirements.
The preparatory activities to pave the way for the effectiveness trial include:
* enrolling infants of the target populations at 6 weeks of age in primary health centers to a randomised, controlled, blinded immunogenicity and safety studies of the Pnc-c
* piloting the crucial EPI activities, randomization and record linkage procedures; upgrading the infrastructure and skills of personnel to meet the standards of Good Clinical Practice (GCP) at the study sites
* setting up vaccinovigilance activities to evaluate the short and long term safety of the study vaccines
* maintaining and setting up surveillance activities and clinical skills to detect cases for the primary endpoint, i.e. pneumonia and severe pneumonia in children 4 to < 23 moths of age both in hospitals and in primary health care settings
* identifying all Pnc pneumonia cases both by standard culture and alternative methods, i.e. antigen detection, and measurement of pneumolysin immune complexes
* within the effectiveness study, follow up a nested cohort of infants for the impact of the Pncc on the upper respiratory tract carriage of Pnc, for establishing serological correlates for protection, and for immunogenicity of the vaccine
* identifying unit costs to measure the cost benefit of the Pnc-c
* establishing monitoring activities to comply with the GCP and ICH guidelines.

Campo scientifico (EuroSciVoc)

CORDIS classifica i progetti con EuroSciVoc, una tassonomia multilingue dei campi scientifici, attraverso un processo semi-automatico basato su tecniche NLP. Cfr.: Il Vocabolario Scientifico Europeo.

È necessario effettuare l’accesso o registrarsi per utilizzare questa funzione

Programma(i)

Programmi di finanziamento pluriennali che definiscono le priorità dell’UE in materia di ricerca e innovazione.

Argomento(i)

Gli inviti a presentare proposte sono suddivisi per argomenti. Un argomento definisce un’area o un tema specifico per il quale i candidati possono presentare proposte. La descrizione di un argomento comprende il suo ambito specifico e l’impatto previsto del progetto finanziato.

Invito a presentare proposte

Procedura per invitare i candidati a presentare proposte di progetti, con l’obiettivo di ricevere finanziamenti dall’UE.

Dati non disponibili

Meccanismo di finanziamento

Meccanismo di finanziamento (o «Tipo di azione») all’interno di un programma con caratteristiche comuni. Specifica: l’ambito di ciò che viene finanziato; il tasso di rimborso; i criteri di valutazione specifici per qualificarsi per il finanziamento; l’uso di forme semplificate di costi come gli importi forfettari.

CSC - Cost-sharing contracts

Coordinatore

NATIONAL PUBLIC HEALTH INSTITUTE
Contributo UE
Nessun dato
Indirizzo
166,Mannerheimintie 166
00300 HELSINKI
Finlandia

Mostra sulla mappa

Costo totale

I costi totali sostenuti dall’organizzazione per partecipare al progetto, compresi i costi diretti e indiretti. Questo importo è un sottoinsieme del bilancio complessivo del progetto.

Nessun dato

Partecipanti (6)

Il mio fascicolo 0 0